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study of 100 adult asthmatics. RESULTS: The table re-
ports outcomes over a 10-year period. Results were driven
by the impact of ICS on quality of life, rather than on
mortality. Findings were stable over most input data
ranges. However, at efficacy levels below 3% and toxic-
ity rates greater than 2.9%, the cost-effectiveness esti-
mate exceeded $100,000/QALY. CONCLUSION: Results
suggest that inhaled steroids deliver good comparative
value in mild-to-moderate adult asthma. More research is
needed, however, on the impact of ICS toxicity on patient
preferences.
CONTRIBUTED POSTER 
PRESENTATIONS
ARTHRITIS, OSTEOPOROSIS &
MUSCULOSKELETAL DISORDERS
PAM1
JOINT COUNTS IN PATIENTS WITH NEW 
ONSET RHEUMATOID ARTHRITIS: PATIENT VS. 
PHYSICIAN ASSESSMENT
Kim SS, Drabinski AM, Williams GR, Formica CA
Knoll Pharmaceutical Company, Mount Olive, NJ, USA
BACKGROUND: Both physician-assessed and patient
self-reported joint counts have been used in the assess-
ment of disease activity in rheumatoid arthritis. The ob-
jective of this study was to compare patient vs. physician
reported joint counts in patients with new onset RA.
METHODS: Baseline data was analyzed from the Study
of New Onset Rheumatoid Arthritis (S.O.N.O.R.A.SM),
a five-year prospective, longitudinal, inception cohort
study to document long-term functional, clinical, and hu-
manistic outcomes and patterns of treatment in patients
with new onset RA. Baseline data collection consisted of
physician and patient surveys. Physicians assessed swol-
len (SJ) and tender/painful joints (TJ) while patients re-
ported painful joint (PJ). Physician’s SJ and TJ consisted
of examination in 64 and 66 joints, respectively. Patient’s
PJ was assessed in 16 joint areas with use of a manne-
quin. The Pearson product moment correlation coeffi-
cient was calculated for SJ, TJ, and PJ counts. RESULTS:
One hundred and seven patients completed the baseline
survey. Mean age of the sample was 55  15 years; 79%
were female; 80% were Caucasian. Mean joint counts were
12.6 (SE  0.9) SJ, 14.0 (SE  1.3) TJ, and 6.6 (SE 
0.4) PJ. Patient-reported PJ correlated with physician-
Strategy Cost QALY $QALY
Quick Relievers alone $5,185 6.77 —
ICS in moderate disease $5,961 6.84 $10,300
ICS in mild disease $7,616 6.93 dominated
ICS in mild/mod. disease $8,392 7.00 $15,000
reported SJ (r  0.22, p  0.023) and TJ (r  0.55, p 
0.001). CONCLUSION: Higher correlation was observed
between PJ and TJ compared to SJ. Patient, self-reported
joint counts may be a useful surrogate of joint activity in
the absence of physician assessment. However, caution
should be taken given that the accuracy of patient, self-
reported joint counts still needs further evaluation. Five-
year follow-up of this population will provide further in-
sight on the sensitivity to change for both patient and
physician reported joint counts as it relates to disease ac-
tivity.
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Osteoporosis affects approximately 24 million Americans
and accounts for an estimated annual direct medical costs
of over $13.8 billion. An economic analysis that evalu-
ates the effectiveness of osteoporosis medications for pre-
vention of bone fractures in a naturalistic setting has not
been formally conducted. OBJECTIVES: To compare
differences among four therapeutic alternatives [estrogen
replacement therapy (ERT), raloxifene, nasal calcitonin,
and alendronate] with respect to health care costs (phar-
macy, medical, and total), and time to fracture. METH-
ODS: Retrospective pharmacy and medical claims data
from a large managed care organization were analyzed.
Patients were included if they were diagnosed with os-
teoporosis and newly initiated on medication between
1/1/98–12/31/98. All patients were followed for exactly 1
year. Cost data was log-transformed to correct for skew-
ness. ANCOVA was conducted to compare total health
care costs; Cox Proportional Hazard Model was per-
formed to compare the risk of fracture. Total health care
costs was defined as all osteoporosis-related services cov-
ered. RESULTS: There were 12,757 female patients iden-
tified for the analysis and the average age was 70(S.D. 
10). A total of 1,721(13.5%) patients had a fracture after
initiation of drug therapy. After adjusting for age, prior
medication costs, prior fracture event, and comorbidities,
adjusted means (95%CI) of log-transformed total health
care costs was lowest for ERT 5.87(5.84–5.90), com-
pared to raloxifene 6.32(6.19–6.46), alendronate
6.55(6.51–6.59) and calcitonin 7.20(6.61–7.80). Com-
pared to calcitonin, the adjusted hazard ratios (95%CI)
for a fracture were 0.174(0.078–0.39) for ERT,
0.175(0.078–0.39) for alendronate, and 0.160(0.068–
0.377) for raloxifene. CONCLUSIONS: In this popula-
tion, ERT was associated with statistically significant
lower total health care costs compared to raloxifene, al-
endronate, and calcitonin. Raloxifene was associated
with statistically significant lower total health care costs
